About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? [email protected]

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clareo Health | Lymphoma Clinical Trials | 6,621 Studies Recruiting

Clinical TrialsLymphoma

Lymphoma Clinical Trials

Browse 6,621 clinical trials for lymphoma. Find studies that match your criteria and connect with research centers.

Find trials near:

New York Los Angeles Chicago Houston Phoenix Philadelphia

Order

Status

RecruitingNot yet recruitingActive, not recruitingEnrolling by invitationCompletedTerminated

Phase

Early phase 1Phase 1Phase 1–2Phase 2Phase 2–3Phase 3Phase 4No phase

Who can join

Healthy volunteers too

Showing 5401-5420 of 6,621 trials

RecruitingZanubrutinib and Lenalidomide as Maintenance Therapy in DLBCLThe goal of this phase 2 trial is to test the safety and efficacy of zanubrutinib and lenalidomide as maintenance therapy in patients with DLBCL.NCT06503263·Beijing, Beijing Municipality CompletedStudy of Nivolumab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) That Have Either Failed or Are Not Eligible for Autologous Stem Cell Transplant (CheckMate 139)The purpose of this study is to determine whether Nivolumab is effective in the treatment of DLBCL in patients that have failed or are ineligible for ASCTNCT02038933·Phoenix, Arizona and 45 others

Related Searches

hodgkintrials non-hodgkintrials

Data from ClinicalTrials.govTerms

CompletedComparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.Multicentric randomized phase III study comparing high doses of chemotherapy with Rituximab followed by auto-transplant HPC versus CHOP plus Rituximab as first line therapy in…NCT00355199·Ancona and 15 others

No longer availableExpanded Access of Imvotamab (IGM-2323) in Patients With R/R NHLExpanded Access of Imvotamab (IGM-2323) in Patients with Relapsed/Refractory Non-Hodgkin Lymphomas from IGM-2323-001 clinical trial.NCT06331832·Nedlands, Western Australia and 2 others

TerminatedIdentification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic LeukemiaB-acute lymphoblastic leukaemia (ALL) is the most common childhood malignancy. Despite enhancement of childhood B-ALL outcome, relapses remain difficult to treat.NCT02618109·Amiens and 17 others

UnknownSafety, Efficacy and Pharmacokinetics of XKDCT023 in DLBCLThis study is a phase I multicenter, single arm, open, dose increasing, single treatment clinical study.NCT05269914

Active not recruitingPembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's LymphomaThis phase II trial tests how well pembrolizumab and tazemetostat work to treat patients who have received autologous stem cell transplantation (ASCT) or chimeric antigen receptor…NCT06242834·Chicago, Illinois and 1 other

CompletedA Pilot Study to Determine the Safety of the Combination of Ontak in Combination With CHOP in Peripheral T-Cell LymphomaThe standard treatment for PTCL is CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy.NCT00337987·New Haven, Connecticut

CompletedZevalin Post-marketing Surveillance in JapanThis study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients who have received Zevalin for relapsed or…NCT01448928·Multiple Locations

CompletedA Study to Describe Treatment Patterns and Disease Control in Participants With cHL and sALCL in Routine Clinical Practice in the Russian FederationThe purpose of this study is to describe patterns of treatment used for cHL and sALCL in real world setting.NCT03942263·Astrakhan and 49 others

CompletedPh I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLLThe purpose of this study is to determine if a subcutaneous (SC) dosing schedule of veltuzumab can be established in NHL or CLL patients and to confirm the safety and efficacy of…NCT00546793·Savannah, Georgia and 4 others

WithdrawnPre-emptive Anakinra for Cytokine Event ReductionObjectives: The primary objective of this study will be to evaluate the impact of pre-emptive use of anakinra on the rate of severe cytokine release syndrome (CRS) following…NCT06703216·Chicago, Illinois

CompletedJapanese Phase Ib/II Copanlisib in Relapsed, Indolent B-cell NHLThe primary objective of this study is to assess the safety profile of copanlisib at the recommended dose (primary endpoint).NCT02342665·Nagoya, Aichi-ken and 12 others

Active not recruitingComparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic LeukemiaThis phase II trial compares the combination of inotuzumab ozogamicin and low intensity chemotherapy and blinatumomab to the usual chemotherapy with blinatumomab in treating…NCT05303792·Birmingham, Alabama and 71 others

CompletedA Study of Remitoro in Participants With Recurrent or Refractory Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma (All Case Study)The primary purpose of the study is to investigate the incidence of adverse drug reactions (ADRs) (ADR of special interest: capillary leak syndrome, infusion reaction…NCT05137847·Nagoya and 2 others

TerminatedA Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.The purpose of this study is to learn about the effects of two study medicines (maplirpacept \[PF-07901801\] and glofitamab) when given together for the treatment of diffuse large…NCT05896163·Kansas City, Kansas and 9 others

RecruitingDose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell MalignanciesThe purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a…NCT06980116·Tbilisi and 16 others

RecruitingMOLyF : Bone Marrow and Follicular LymphomaThis is a prospective single-center study designed to assess potential differences in cell composition between bone marrows of patients with follicular lymphoma and those from…NCT06608147·Rennes

UnknownRituximab Maintenance Therapy in Aggressive CD20 (Cluster of Differentiation Antigen 20) Positive Lymphoma and Mantle Cell LymphomaClinical and pharmacokinetic data suggest that the effect of rituximab could be improved by prolonged exposure to the drug.NCT01933711·Heidelberg, Baden-Wurttemberg and 2 others

CompletedCoproporphyrine Isomers and Methotrexate EliminationHigh dose methotrexate (MTX) is responsible of severe toxicity in patients in whom elimination from plasma is delayed.NCT00822432·Paris and 1 other

PreviousPage 271 of 332Next